Long-Term Data Confirm TH Benefit in Early HER2-Positive Breast Cancer

This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Source: CancerNetwork - June 30, 2017 Category: Cancer & Oncology Authors: Sara M. Tolaney, MD, MPH Tags: News Videos Breast Cancer Source Type: news